• Complete panel for the detection of the HSV infection (HSV IgG, HSV IgM)
  • Low cross reactivity with other Herpesvirus family immunoglobulins

The HSV 1/2 IgM test is a chemiluminescent immunoassay (CLIA), for use on IDS automated analyzers,  for quantitative determination of specific IgM class antibodies directed against the Herpes Simplex Virus type 1 and 2 (HSV 1/2) in samples of human serum or plasma (K3-EDTA, Sodium Citrate).

This assay is used as a diagnostic aid when assessing HSV type 1 and 2 infections.

Type 1 and 2 Herpes Simplex viruses (HSV 1, HSV 2) belong to the Herpesviridae family, in the Alphaherpesvirus subfamily and both are human pathogens. Approximately one third of the population are hosts to the latent form of the virus and are sources of infection in periods of productive activation of the virus.

HSV infections are classed as primary and recurrent and are highly prevalent in the population1.

HSV 1 is normally associated with infections in the oropharyngeal and eye areas, while HSV 2 is the cause of most genital and neonatal infections2,3.

Diagnosis of primary infections is based on detection of specific IgM class antibodies as well as to demonstrate seroconversion or a significant increase in the concentration between acute and convalescent sera7.

The use of recombinant membrane glycoproteins specific for the type of virus makes possible to distinguish exactly the patient’s immune status. The specific recombinant glycoproteins are gG1 for the type 1 virus and gG2 for the type 2 virus. They are used both to monitor the primary infection, by detecting the specific IgM antibodies, and the patient’s immune status, by detecting the specific IgG antibodies9

  1. Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006; 296: 964-973. [PubMed:16926356]
  1. Chayavichitslip P, Buckwalter JV, Krakowski AC, Friedlander SF. Herpes Simplex. Pediatr Rev. 2009; 30(4):119-29.
  1. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2002. MMWR 2002: 51 (No. RR-6)
  1. Lamey Pj, Hyland PL. Changing epidemiology of herpes simplex type 1 infections. Herpes 199; 6:20-24.
  1. Nieuwenhuis RF,van Doorum Gj, Mulder PG, et al. Importance of herpes simplex virus type 1 (HSV 1) in primary genital herpes. Acta Derm Venereol 2006;86: 129-134.[PubMed:16648915]
  1. Lycke E and Jeansson S: Herpes Simplex Virus. in EH Lenette, P Halonen and FA Marphy, eds. Laboratory Diagnosis of Infectious Diseases: Principals and Practice, vol. II: Viral, Rickettsial and Clamydial diseases, Springer-Verlag, Berlin, pp211,1988.
  1. Drew WL and Rawls WE. Herpes simplex viruses, in EH Lenette, A Ballows, WJ Hausler and HJ Shadomy, eds, Manual of Clinical Microbiology, 4th, American Society for Microbiology, Washington, DC, pp 705, 1985.
  1. Arvin A, C Prober. Herpes Simplex Virus. 876-883. In Murray P, E Baron, M Pfaller, F Tenover, and R Yolken (eds). Manual of Clinical Microbiology. 6th ASM, Washington D.C. (1995).
  1. Bergström T, Trybala E. Antigenic differences between HSV 1 and HSV 2 glycoproteins and their importance for type-specific serology. Intervirology. 1996; 39 (3): 176-84.